Literature DB >> 10629660

Tumour markers CEA, NSE, SCC, TPA and CYFRA 21.1 in resectable non-small cell lung cancer.

P Foa1, M Fornier, R Miceli, E Seregni, L Santambrogio, M Nosotti, I Cataldo, M Sala, S Caldiera, E Bombardieri.   

Abstract

BACKGROUND: In the last few years, several prognostic factors have been investigated in order to identify among patients with completely resected non-small cell lung cancer (NSCLC) subsets at high risk of recurrence. In this context, the actual role of serum tumour markers is still unclear. The aim of this study was to evaluate the prognostic significance of preoperative CEA, NSE, SCC, TPA and CYFRA 21.1 serum levels in 62 patients submitted to radical surgery for non-small cell lung cancer (NSCLC). The predicting ability of these tumour markers with respect to histological type and pathological stage was also assessed. PATIENTS AND METHODS: After informed consent was obtained, the preoperative serum concentrations of the tumour markers CEA, NSE, SCC, TPA and CYFRA 21.1 were measured by means of immunometric assays in 62 patients referred to our Institutions from January to December 1992. All patients had resectable, histologically proven NSCLC and were submitted to radical surgery. Overall survival (OS) was calculated as the time elapsed from surgery to the date of death or last clinical evaluation; the prognostic effect of the tumour markers was investigated by Cox multiple regression models.
RESULTS: Fifty-six patients were male and 6 female; median age was 62 years. Thirty-four patients had a histological diagnosis of adenocarcinoma and 28 of squamous cell carcinomas. With regard to pathological stage, 32 patients had stage I, 4 patients had stage II and 23 patients had stage IIIA disease. In this series of patients, at a median follow-up of 55 months after surgery, we found that both TPA and CYFRA 21.1 serum levels at the time of diagnosis were reliable predictors of overall survival high values of these markers being associated with worse prognosis.
CONCLUSIONS: Our findings suggest that in completely resected NSCLC, TPA and CYFRA 21.1 preoperative serum levels might provide a useful tool for stratifying subgroups of patients with different chances of disease recurrence after surgery.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10629660

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  30 in total

1.  Quantifying the expression of tumor marker genes in lung squamous cell cancer with RNA sequencing.

Authors:  Lin Wang; Cheng Zhan; Yongxing Zhang; Jun Ma; Junjie Xi; Wei Jiang; Yu Shi; Qun Wang
Journal:  J Thorac Dis       Date:  2014-10       Impact factor: 2.895

2.  Antiproliferative and antioxidant potential of beta-ionone against benzo(a)pyrene-induced lung carcinogenesis in Swiss albino mice.

Authors:  Selvamani Asokkumar; Chandrashekar Naveenkumar; Subramanian Raghunandhakumar; Sattu Kamaraj; Pandi Anandakumar; Sundaram Jagan; Thiruvengadam Devaki
Journal:  Mol Cell Biochem       Date:  2011-12-21       Impact factor: 3.396

3.  Identification of serum miRNAs by nano-quantum dots microarray as diagnostic biomarkers for early detection of non-small cell lung cancer.

Authors:  Lihong Fan; Huiwei Qi; Junliang Teng; Bo Su; Hao Chen; Changhui Wang; Qing Xia
Journal:  Tumour Biol       Date:  2015-12-22

4.  Evaluation of the clinical application of multiple tumor marker protein chip in the diagnostic of lung cancer.

Authors:  Xiaochuan Wang; Yi Zhang; Liangqi Sun; Shuaiping Wang; Jing Nie; Wenqing Zhao; Guobao Zheng
Journal:  J Clin Lab Anal       Date:  2018-05-07       Impact factor: 2.352

5.  Potential application of non-small cell lung cancer-associated autoantibodies to early cancer diagnosis.

Authors:  Yibing Yao; Yu Fan; Jun Wu; Haisu Wan; Jing Wang; Stephen Lam; Wan L Lam; Luc Girard; Adi F Gazdar; Zhihao Wu; Qinghua Zhou
Journal:  Biochem Biophys Res Commun       Date:  2012-06-16       Impact factor: 3.575

Review 6.  History, molecular features, and clinical importance of conventional serum biomarkers in lung cancer.

Authors:  Haruhiko Nakamura; Toshihide Nishimura
Journal:  Surg Today       Date:  2017-02-22       Impact factor: 2.549

7.  The level of serum carcinoembryonic antigen is a surrogate marker for the efficacy of EGFR-TKIs but is not an indication of acquired resistance to EGFR-TKIs in NSCLC patients with EGFR mutationsm.

Authors:  Jingquan Han; Yuzhang Li; Shouqiang Cao; Qing Dong; Guibin Zhao; Xiangyu Zhang; Jian Cui
Journal:  Biomed Rep       Date:  2017-05-19

Review 8.  Prognostic and predictive biomarkers in early stage NSCLC: CTCs and serum/plasma markers.

Authors:  Philip A J Crosbie; Rajesh Shah; Yvonne Summers; Caroline Dive; Fiona Blackhall
Journal:  Transl Lung Cancer Res       Date:  2013-10

9.  Using protein microarray as a diagnostic assay for non-small cell lung cancer.

Authors:  Li Zhong; Giovanna E Hidalgo; Arnold J Stromberg; Nada H Khattar; James R Jett; Edward A Hirschowitz
Journal:  Am J Respir Crit Care Med       Date:  2005-08-18       Impact factor: 21.405

10.  Correlation between combining 18F-FDG PET/CT metabolic parameters and other clinical features and ALK or ROS1 fusion in patients with non-small-cell lung cancer.

Authors:  Maomei Ruan; Liu Liu; Lihua Wang; Bei Lei; Xiaoyan Sun; Cheng Chang; Yan Shen; Wenhui Xie
Journal:  Eur J Nucl Med Mol Imaging       Date:  2020-01-03       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.